

APR 30 2004
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael PATANE

Attorney Docket No.: CASM122094

Application No.: 10/733,857

Filed: December 11, 2003

Title: EXTRACTING AND PURIFYING ENZYMES

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

April 26, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.


1. X Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. , filed . The references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application.
3. A concise explanation of the relevance of document Cite No. (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided in an English abstract appended to said document.
4. This Information Disclosure Statement is being filed concurrently with the above-identified application.
5. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
6. Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, and is accompanied by:

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- a. _____ a certification statement as specified in 37 C.F.R. § 1.97(e); or
- b. _____ the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$180.00 is enclosed.
7. _____ Pursuant to 37 C.F.R. § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before or simultaneous with payment of the issue fee. The Information Disclosure Statement is accompanied by a certification statement as specified in 37 C.F.R. § 1.97(e) and the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$180.00 is enclosed.
8. _____ Pursuant to 37 C.F.R. § 1.704(d), this Information Disclosure Statement is accompanied by a statement that each item of information contained in this Information Disclosure statement was cited in a communication from a foreign patent office in a counterpart application. Such communication was received by an individual designated in 37 C.F.R. § 1.56(c) on _____, which is not more than thirty days prior to the filing of this Information Disclosure Statement.
9. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



Gary S. Kindress
Registration No. 22,178
Direct Dial No. 206.695.1702

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop ~~Missing Page~~ Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date: April 27, 2004
GSK/PAS:bmc



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANT(S) THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicant: Michael PATANE Attorney Docket No. CASM122094
Application No.: 10/733,857
Filed: December 11, 2003
Title: EXTRACTING AND PURIFYING ENZYMES

U.S. PATENT DOCUMENTS

*Examiner Cite	Kind	Date	
Initials No.	Document No.	Code	(mm/dd/yyyy) Name
None			

FOREIGN PATENT DOCUMENTS

*Examiner Cite	Kind	Publication Date	Country	English
Initial No.	Document No.	Code	(mm/dd/yyyy)	Abstract Translation
				Provided Provided
None				

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Cite	
Initial No.	
_____ O1	Chae, H.J., et al., "Utilization of Brewer's Yeast Cells for the Production of Food-Grade Yeast Extract. Part 1: Effects of different enzymatic treatments on solid and protein recovery and flavour characteristics", Bioresource Technology 76(3):253-258, 2000.
_____ O2	Kozma, P., et al., "Purification and Properties of a Phosphodiesterase and Nucleotide Pyrophosphatase From Root Callus Tissues of Vine Shoots", Acta Agronomica Academiae Scientiarum Hungaricae 28(3-4):281-294, 1979.
_____ O3	La Marra-Phillips, A., "A Study of Phosphodiesterase in the fission yeast Schizosaccharomyces Pombe", UMI, Order No. DA9818617, From: Diss Abstr. Int., B 58(12):6377, 1998.
_____ O4	Nakabayashi, T., et al., "Phosphodiesterase I in Cultured Cells of <i>Mentha Arvensis</i> ", Phytochemistry 39(5):1013-1016, 1995.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- _____ O5 Sander, M., et al., "Partial Purification of Pde1 from *Saccharomyces cerevisiae*: Enzymatic Redundancy for the Repair of 3'-Terminal DNA Lesions and Abasic Sites of Yeast", *Biochemistry* 36(20):6100-6106, 1997.
- _____ O6 Ueda, N., et al., "Marked Activation of the *N*-acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations", *Biochimica et Biophysica Acta* 1532(1-2):121-127, 2001.
- _____ O7 Vogel, A., et al., *ElaC* Encodes a Novel Binuclear Zinc Phosphodiesterase", *Journal of Biological Chemistry* 277(32), 29078-29085, 2002.
- _____ O8 Washburn, K.B., et al., "Comparison of Mechanical Agitation and Calcium Shock Methods for Preparation of a Membrane Fraction Enriched in Olfactory Cilia", *Chemical Senses* 27(7):635-642, September 2002.
- _____ O9 Wold, W.S.M., et al., "Demonstration in *Aspergillus niger* of adenyl cyclase, a cyclic adenosine 3',5'-monophosphate-binding protein, and studies on intracellular and extracellular phosphodiesterases" *Canadian Journal of Microbiology*, 20(11):1567-1576, 1974.
- _____ O10 Yu, J., et al., "Identification and Characterisation of a Human Calmodulin-Stimulated Phosphodiesterase PDE1B1", *Cellular Signalling* 9(7):519-529, November 1997.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GSK/PAS:bmc

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100